toxylact
The first professional lActological database in the word
A09AB01 — Glutamic Acid
Toxicological and Lactological Monograph
A09AB01 corresponds to glutamic acid, classified within ATC group A09AB, “acid preparations,” under digestive agents. In clinical and nutritional contexts, glutamic acid is an endogenous non-essential amino acid with central roles in protein metabolism, nitrogen transport, intermediary metabolism, and neurotransmission. Its use as an exogenous digestive acidifier is uncommon in contemporary practice, and the lactation risk is expected to be very low when it is used in conventional oral medicinal doses.
ATC class and general pharmacology
ATC classification
|
ATC level |
Classification |
|
A |
Alimentary tract and metabolism |
|
A09 |
Digestives, including enzymes |
|
A09A |
Digestives, including enzymes |
|
A09AB |
Acid preparations |
|
A09AB01 |
Glutamic acid |
The ATC system assigns medicinal substances according to their principal therapeutic use and their anatomical, pharmacological, and chemical characteristics. A09AB01 is therefore placed among digestive acid preparations rather than among central nervous system drugs, despite glutamate’s physiological role as the major excitatory neurotransmitter in the brain.who+1
Pharmacological characteristics
Glutamic acid is a naturally occurring acidic amino acid. At physiological pH, it largely exists as glutamate, its anionic form. It is abundant in dietary proteins and is also synthesized endogenously from intermediary metabolic precursors, particularly alpha-ketoglutarate.
Its principal physiological roles include:
- Participation in protein synthesis and general nitrogen metabolism.
- Formation of glutamine through glutamine synthetase, an important pathway for nitrogen transport and ammonia detoxification.
- Contribution to cellular energy metabolism through reversible conversion to alpha-ketoglutarate, an intermediate of the tricarboxylic-acid cycle.
- Provision of precursor substrate for gamma-aminobutyric acid, an inhibitory neurotransmitter, through glutamate decarboxylase.
- Function as the predominant excitatory neurotransmitter in the mammalian central nervous system.
When administered orally, glutamic acid undergoes substantial metabolism in the gastrointestinal tract and liver. Enterocytes use dietary glutamate extensively as a metabolic substrate. Consequently, systemic exposure after ordinary oral intake is limited relative to the amount ingested, and a large fraction does not circulate unchanged in peripheral blood.
The historical rationale for use as a digestive acid preparation relates to its acidic properties and possible support of gastric digestive conditions. However, it should not be considered a substitute for evidence-based investigation and treatment of clinically significant dyspepsia, malabsorption, pancreatic insufficiency, gastric hypochlorhydria, inflammatory gastrointestinal disease, or other causes of persistent digestive symptoms.
Toxicological profile
General toxicology
Glutamic acid is a normal constituent of human tissue, food proteins, maternal plasma, and human milk. Toxicological interpretation must therefore distinguish between ordinary physiological exposure and non-physiological exposure patterns, particularly very high doses, parenteral administration, impaired metabolic handling, or experimental direct central nervous system exposure.
Oral glutamic acid has relatively low inherent systemic toxicity in healthy individuals because it is efficiently metabolized by the intestinal mucosa, liver, and peripheral tissues. The pharmacokinetic handling of oral glutamate limits delivery of large quantities of unchanged glutamate to the systemic circulation and, especially, to the brain.
At usual oral medicinal or nutritional doses, clinically important adverse effects are uncommon. Potential dose-related gastrointestinal effects may include:
- Nausea.
- Abdominal discomfort.
- Dyspepsia or epigastric burning.
- Altered bowel habits, including loose stools in susceptible individuals.
- Symptoms related to the acidity or formulation excipients rather than glutamic acid itself.
Neurotoxicity considerations
Glutamate is capable of producing excitotoxic neuronal injury when excessively activating glutamate receptors in the central nervous system. This mechanism is relevant to neurological injury models and contributes to the pathophysiology of conditions such as cerebral ischemia, traumatic brain injury, seizures, and certain neurodegenerative processes.
However, this mechanism should not be extrapolated directly to ordinary oral administration of glutamic acid. Several protective physiological factors limit central exposure:
- Extensive first-pass utilization by intestinal and hepatic tissues.
- Tight regulation of plasma amino-acid concentrations.
- Restricted passage of glutamate across the blood–brain barrier.
- Efficient uptake and metabolic recycling of glutamate within the central nervous system.
Thus, the theoretical concept of glutamate excitotoxicity does not, by itself, establish a clinically meaningful neurotoxic risk to a breastfed infant from maternal oral use of glutamic acid at customary doses.
Populations requiring additional caution
Caution is reasonable in mothers with:
- Significant hepatic dysfunction, particularly if associated with impaired nitrogen metabolism or hyperammonaemia.
- Severe renal impairment, where amino-acid and acid–base handling may be altered.
- Severe metabolic disorders affecting amino-acid metabolism.
- Unexplained neurological symptoms, recurrent seizures, or serious acute illness.
- Marked gastrointestinal disease in which the prescribed formulation could aggravate symptoms.
These cautions principally concern maternal clinical management. They do not automatically indicate a breastfeeding contraindication, but they may change the maternal benefit–risk assessment and warrant individualized medical review.
Lactation pharmacology and infant exposure
Physiological presence in human milk
Glutamic acid and glutamate are normal components of human milk. Free glutamate is among the more abundant free amino acids in mature human milk, and milk also contains glutamate incorporated into proteins. Consequently, breastfed infants are physiologically exposed to glutamate as a natural nutritional constituent of human milk.
This background exposure is important for risk interpretation: maternal administration of glutamic acid does not introduce a completely foreign pharmacological substance into milk. Instead, it concerns possible alteration of exposure to an endogenous amino acid already present in human milk and routinely consumed by the infant.
Expected transfer into milk
Direct, formulation-specific milk concentration studies for medicinal glutamic acid are limited. Nevertheless, clinically meaningful transfer leading to pharmacological infant exposure is unlikely after conventional maternal oral use for several reasons:
- Glutamic acid is extensively metabolized during gastrointestinal absorption and first-pass passage through the intestinal mucosa and liver.
- Systemic concentrations are homeostatically regulated.
- It is a normal constituent of maternal plasma and milk rather than a lipophilic xenobiotic that readily concentrates in milk.
- Any minor increment in milk glutamate would enter a milk matrix that already naturally contains glutamate.
- The nursing infant metabolizes dietary amino acids through normal gastrointestinal and systemic metabolic pathways.
The usual relative infant dose calculation is most useful for drugs that appear in milk as unchanged active pharmaceutical compounds. For glutamic acid, interpretation is less straightforward because it is an endogenous nutrient-like substance, is naturally present in milk, and is subject to rapid metabolic interconversion. A numerical relative infant dose should therefore not be inferred in the absence of direct paired maternal plasma–milk pharmacokinetic studies.
Infant oral bioavailability and clinical relevance
Even if a modest maternal treatment-related increase in milk glutamate were to occur, the clinical significance for a healthy term infant would be expected to be low. The infant normally receives glutamate from human milk proteins and from the free amino-acid fraction of milk. Gastrointestinal metabolism further reduces the likelihood that ingested milk glutamate would produce sustained pharmacologically active systemic concentrations.
This assessment differs materially from direct intravenous glutamate exposure, high-dose experimental exposure, or pathological states with disrupted metabolic regulation. Such scenarios are not comparable to routine maternal oral administration of A09AB01 preparations.
Evidence limitations
The main limitation is the scarcity of direct, high-quality lactation pharmacokinetic data specifically evaluating maternal medicinal glutamic acid administration, concentrations in human milk, infant serum concentrations, and systematically documented infant outcomes.
Accordingly, the safety conclusion rests primarily on:
- The endogenous nature of glutamic acid.
- Its normal occurrence in human milk.
- Extensive presystemic metabolism following oral administration.
- Low expectation of clinically relevant systemic maternal and infant exposure.
- Absence of a plausible mechanism by which standard maternal oral doses would produce toxic infant glutamate exposure.
This is a biologically well-supported assessment, but it should not be presented as equivalent to extensive prospective mother–infant outcome data.
Lactological safety assessment and clinical recommendations
Overall lactological assessment
Glutamic acid (A09AB01) is generally compatible with breastfeeding when used orally at standard therapeutic doses. The anticipated risk to a healthy full-term breastfed infant is low.
The principal rationale is that glutamic acid is endogenous, naturally present in human milk, extensively metabolized after oral ingestion, and unlikely to reach breast milk in amounts capable of causing pharmacological or toxicological effects in the infant. The broader LactMed framework recognizes that some digestive enzyme therapies, such as pancrelipase, are minimally absorbed from the maternal gastrointestinal tract and are considered acceptable during breastfeeding; although glutamic acid is pharmacologically distinct, the same principle of negligible clinically relevant infant exposure after maternal gastrointestinal use supports a low-risk approach where systemic absorption is limited.ncbi.nlm.nih
Clinical recommendations
- Breastfeeding can usually continue during maternal oral treatment with glutamic acid at customary doses.
- Use the lowest effective dose for the shortest clinically appropriate duration, especially if the indication is uncertain or symptoms are self-treated.
- Evaluate the underlying gastrointestinal complaint rather than relying on prolonged empiric treatment with digestive acid preparations.
- No interruption of breastfeeding, milk expression and discarding, or routine dose-timing strategy is expected to be necessary.
- Maternal administration immediately after a feed may be used for reassurance, but this timing measure is not pharmacologically required in routine use.
- Monitor the infant clinically if maternal doses are unusually high, if multiple medicines are being used, or if the infant is premature, medically unstable, has significant hepatic or renal impairment, or has a known metabolic disorder.
- Seek paediatric review if the infant develops persistent vomiting, poor feeding, unusual irritability, diarrhoea, failure to gain weight, lethargy, or other unexplained symptoms. Such events would be nonspecific and are not expected from ordinary maternal glutamic acid exposure, but they warrant clinical assessment.
- Review the complete product formulation. Combination products may contain additional active substances, acids, enzymes, alcohol, sweeteners, herbal constituents, or excipients with a different lactation profile from glutamic acid alone.
Practical conclusion
For a healthy lactating woman using an oral A09AB01 glutamic-acid preparation, the expected infant exposure through breast milk is minimal and is unlikely to exceed the range of physiological relevance. Breastfeeding should generally be supported and continued. Individualized assessment is advisable only when maternal illness is severe, dosing is atypical, the product contains additional active ingredients, or the infant is preterm or medically vulnerable.



